The Journal of Nuclear Medicine - JNM

PET/CT may be predictive of treatment response in patients with mCRPC, regardless of ongoing systemic therapy. Response assessed by is a potentially more significant prognostic factor than PSA for PFS. http://ow.ly/Rw0t50MuquB

Towards practical and feasible dosimetry: http://ow.ly/8ER650MzqKE. Let’s do it!

Hot topic: The latest advances in PRRT for gastroenteropancreatic neuroendocrine tumors from Drs. Hindié, Baudin, Hicks and Taïeb. http://ow.ly/v0Fu50MuqsX

= Precision Oncology

A helpful standardized tool to monitor relevant symptoms/toxicities in radionuclide therapy trials and real-world settings. http://ow.ly/SJCU50Muqqx

To both improve therapeutic efficacy and reduce adverse events, accurate monitoring of the activation of T-cells is required. http://ow.ly/PLiP50MogqH

= Precision Immunology

Nearly half of patients with non-small cell are not staged according to national guidelines. This is linked to greater mortality rates, according to The Journal of Nuclear Medicine. http://ow.ly/XJhn50MueT1

Chronic traumatic encephalopathy--a primary tauopathy--has been shown to be strongly associated with repetitive . http://ow.ly/Wu7r50MogpP

Industry invests in : a discussion with Dr. Ken Song. http://ow.ly/UESh50Moglx

Learn about the future of oncology and therapy: http://ow.ly/hhTz50Mogf9

and = Precision Oncology

A novel PET radiotracer can reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for . http://ow.ly/KyHx50Mofcp

⁶⁸Ga-PSMA11 PET-based response criteria (PPP, aPERCIST, aPCWG3) have high prognostic utility in men with metastatic undergoing taxane-based chemotherapy. http://ow.ly/AeIQ50MiA3a

= Prognostication

Peter Maliha provides a rare, illustrated post: A pitfall for FAPi imaging. http://ow.ly/UOQA50MizWV

A large single-center investigation provides insights into FAP expression in various cancers and compares FAPi with FDG PET/CT. http://ow.ly/EyYY50MizMV

= Precision Diagnosis and Therapy

Good idea and easily available; let’s go for indication approval and reimbursement! http://ow.ly/cSoE50Mf4pw

Happy and healthy New Year from the JNM team to all readers, reviewers, authors, and contributing scientists!

Dr. Pomykala: To tackle the “last mile” we need drug supply, competent staff (including authorized users), sufficient reimbursement, and informed referring physicians. http://ow.ly/QNx250Mf4mA

= Precision Oncology

Do we need FDG PET/CT prior to PSMA-targeted radiopharmaceutical therapy? http://ow.ly/c2v150M9ozN

Read what's coming: 2022 Annual Meeting highlights lecture on oncology and therapy. http://ow.ly/iQHq50LZLTj

Total metabolic tumor volume tumor dissemination calculated from only two PET MIP images are prognostic biomarkers in DLBCL patients and can be automatically estimated using an algorithm. http://ow.ly/N4w650LZLFx

Low-dose (7.4 kBq) TAT combined with immunocytokine regimen gives superior tumor reductions and survival curves compared with monotherapy in breast and colon cancer tumor models. http://ow.ly/Imei50LZLl0

Building trust: A prerequisite for using AI in (nuclear) medicine. http://ow.ly/vtgj50M9puC

This is how you do it: Joint EANM, SNMMI, and IAEA enabling guide on how to set up a center. http://ow.ly/kbpb50LZLfk

Theranostics = Precision Oncology

Nanoparticle diagnostics and in the clinic: Are we close to clinical impact? https://doi.org/10.2967/jnumed.122.263895

⁶⁸Ga-PSMA-11 PET can risk-stratify patients with intermediate- or high-grade before prostatectomy based on degree of uptake in the prostate and presence of metastatic disease. http://ow.ly/HNrK50LZL4P

Educate yourself and others: What does it take to get a drug approval? http://ow.ly/uByk50LZKRu

Dr. Murphy: A message for the readership of is that and can partner really well together. http://ow.ly/2x0350LZKP4

Whole-body PET imaging: A catalyst for whole-person research? http://ow.ly/rJV150LZKLR

Understanding false positive findings: Experience matters in next-generation cancer imaging. http://ow.ly/RfwF50LZKIU

Imaging adaptive immune responses to immunotherapies to improve outcomes. http://ow.ly/9Evr50LZtxz

=

As expected, ¹⁸F-PSMA is superior to ¹⁸F-fluorocholine for detection of biochemical recurrence, according to a prospective phase III trial by Olivier and colleagues. http://ow.ly/Gql550LSWWv

=

Including ¹⁸F-fluciclovine PET/CT into SRT leads to survival benefits in patients with PSA

Increased uptake of the PSMA ligand ¹⁸F-rhPSMA-7.3 by axillary lymph nodes is common after vaccination and can last for 8 weeks. This should be considered in the interpretation of ¹⁸F-rhPSMA-7.3 PET/CT. http://ow.ly/EcR350LwOiV

Dr. Valentin Fuster discusses heart health with Dr. Marcello di Carli: “My message to a young audience is invest in what you are passionate about and interested in and listen to your mentors.” http://ow.ly/MPco50LwO4H

Hot spot imaging: Indications discussed include myocardial viability, myocardial inflammation, device or valve infection, large vessel vasculitis, and more. http://ow.ly/UZZb50LwNFz

Cardiac = Precision

PSMA PET/CT by RECIP 1.0 is prognostic for overall survival and can be used as a response biomarker to monitor early efficacy of ¹⁷⁷Lu-PSMA in men with mCRPC. http://ow.ly/6iGr50LwNqy

=

Emmet et al report a PRIMARY score incorporating intraprostatic pattern and intensity on ⁶⁸Ga-PSMA PET/CT shows potential with high diagnostic accuracy for clinically significant . http://ow.ly/pB1l50LwN4B

Bellavia et al introduce basic TRT radiobiology and survey emerging and clinically translated TRT agents that have been combined with immune checkpoint inhibitors. http://ow.ly/ieFP50LwMzl

=

Continuing Education from : Learn about oligometastatic . https://jnm.snmjournals.org/content/63/11/1628

=

Explainable predictions lead to meaningful improvements in physician interpretation of myocardial perfusion images. http://ow.ly/el6K50LwMfe

CXCR4 for targeted imaging…now on to CXCR4 targeted therapy? http://ow.ly/s3Cy50LwM9l